Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 2/20 | 0.41 |
| ▸ | HSD17B13 | Q7Z5P4 | 13/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.35 |
| ▸ | ESR1 | P03372 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15671151 | 0.93 | TNF (0.45) | TNFHSD17B13MAPTADORA2BESR2 | |
| SCHEMBL15670839 | 0.80 | SYK (0.39) | ESR2ESR1 | |
| SCHEMBL17193084 | 0.77 | HSD17B13 (0.38) | TNFHSD17B13ESR2ESR1 | |
| SCHEMBL15671112 | 0.77 | TNF (0.57) | TNFMAPTADORA2B | |
| SCHEMBL17191910 | 0.73 | ESR2 (0.36) | HSD17B13ESR2ESR1 | |
| SCHEMBL17192041 | 0.71 | TNF (0.47) | TNFMAPTADORA2B | |
| SCHEMBL15670874 | 0.68 | TNF (0.72) | TNFMAPTADORA2B | |
| SCHEMBL17181483 | 0.66 | TNF (0.47) | TNF | |
| SCHEMBL17192032 | 0.65 | HDAC6 (0.46) | TNFMAPTADORA2B | |
| SCHEMBL874574 | 0.64 | CYP1A2 (0.59) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10174053-B2 | 2 substituted cephem compounds | GLAXO GROUP LIMITED (GB) | 2019-01-08 | — | — | US | disclosed |
| US-10174053-B2 | 2 substituted cephem compounds | GLAXO GROUP LIMITED (GB) | 2019-01-08 | — | — | US | disclosed |
| US-20170281532-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2017-10-05 | — | — | US | disclosed |
| US-20170281532-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2017-10-05 | — | — | US | disclosed |
| US-20170281532-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2017-10-05 | — | — | US | disclosed |
| US-20150299223-A1 | 2-SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LTD (GB) | 2015-10-22 | — | — | US | disclosed |
| US-20150299223-A1 | 2-SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LTD (GB) | 2015-10-22 | — | — | US | disclosed |
| US-20150299223-A1 | 2-SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LTD (GB) | 2015-10-22 | — | — | US | disclosed |
| EP-2917223-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | Glaxo Group Limited (GB) | 2015-09-16 | — | — | EP | disclosed |
| WO-2014068388-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2014-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281532-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | CEP170, CES2, CMBL | TNF 2990/4885HSD17B13 2401/4885MAPT 1744/4885 |
| US-20150299223-A1 | 2-SUBSTITUTED CEPHEM COMPOUNDS | CEP170, ABL1, CEPT1 | TNF 1673/4885HSD17B13 3579/4885MAPT 2852/4885 |
| US-10174053-B2 | 2 substituted cephem compounds | CEP170, CES2, CMBL | TNF 2990/4885HSD17B13 2401/4885MAPT 1744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.